News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...
Shell (NYSE:SHEL) has denied a report that it is in talks to acquire oil rival BP (NYSE:BP). “This is further market ...
Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.
On behalf of an individual investor, Block & Leviton LLP filed a class action lawsuit today against Hims & Hers Health, Inc. (NYSE: HIMS), along with certain individuals, alleging that they violated ...
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” ...
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations ...
MarketBeat on MSN2d
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingGross profit margins are typically a sign of strong (or weak) pricing power and market share, and a 73% margin tells investors all they need to know. Hims & Hers is an industry leader, and its ...
Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback